FORT LAUDERDALE, FL--(Marketwired - April 07, 2014) -
A leading US specialty pharmaceutical company focused on the development and commercialization of novel medicines has selected OmniComm Systems, Inc.'s (OTCQB: OMCM
), TrialMaster for three clinical studies comprising a Phase II, Phase III, and safety and pharmacokinetic study.
A pioneer in the field of novel therapies, this specialty pharma's choice of OmniComm's technology reflects their commitment to best-in-class EDC technology in its development of therapies to prevent and treat a wide range of disease states.
Due to the unique nature of their research, the company specifically sought technology that would be easy to learn and intuitive to use for clinicians participating in these clinical studies. Through TrialMaster, their researchers will use a single interface for data capture, data management and reporting. TrialMaster also includes embedded eLearning, allowing their clinicians to easily learn the system and initiate trials quickly.
The company also selected IVR Clinical Concepts (IVRCC) secure Interactive Voice and Interactive Web Response applications (IVR/IWR) that interfaces seamlessly with TrialMaster for efficient patient recruitment and randomization.
"TrialMaster's open architecture offers a quick and easy, configurable method for data consolidation and integration with best-in-class systems such as IVRCC's IWR technology. The market has realized that OmniComm is the specialist in EDC technologies" said Dr Kuno van der Post, SVP business development. "We're excited to work with this leading specialty pharmaceutical company to help them tap into the power of TrialMaster to support the development of their pioneering therapies."
About OmniComm Systems
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm, TrialMaster, TrialOne, eClinical Suite and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.